Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DEVRDN · Entity 4316 | Chief Medical Officer | February 08, 2023 | February 10, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Viridian Therapeutics, Inc.\DE
Report date February 08, 2023 · Filed February 10, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.20 · Expires 2033-02-08 | Direct | 108,000 |
Reported balance
After 2023-02-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-08 · Grant · Acquired 108,000 · Balance 108,000 F1: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2023 Filed Feb 10, 2023 21:54 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 108,000 | $0.00 Strike: $34.20 | $0.00 |
DisclosureSEC source: 0000899243-23-004595 · doc4.xml · derivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 108,000 Underlying: Common Stock · 108,000 shares Expires 2033-02-08 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 8, 2027, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,853 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · derivative · entry 6 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,000 Underlying: Common Stock · 24,853 shares Expires 2031-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 24,853 | $37.21 | $924,780.13 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · nonDerivative · entry 4 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 24,853 | $23.03 | $572,364.59 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · nonDerivative · entry 3 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,853 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,147 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · derivative · entry 5 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 291,853 Underlying: Common Stock · 4,147 shares Expires 2031-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 4,147 | $37.01 | $153,480.47 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · nonDerivative · entry 2 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 13, 2023 Filed Jan 18, 2023 22:58 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 4,147 | $23.03 | $95,505.41 |
DisclosureSEC source: 0000899243-23-002075 · doc4.xml · nonDerivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,147 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 47,377 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · derivative · entry 6 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,000 Underlying: Common Stock · 47,377 shares Expires 2031-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 47,377 | $35.30 | $1,672,408.10 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · nonDerivative · entry 4 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.76 to $35.934. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 47,377 | $23.03 | $1,091,092.31 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · nonDerivative · entry 3 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,623 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · derivative · entry 5 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 343,377 Underlying: Common Stock · 12,623 shares Expires 2031-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | SaleCommon Stock | 12,623 | $33.04 | $417,063.92 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · nonDerivative · entry 2 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $33.00 to $33.135. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 00:09 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | Exercise / conversionCommon Stock | 12,623 | $23.03 | $290,707.69 |
DisclosureSEC source: 0000899243-23-001626 · doc4.xml · nonDerivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 23:13 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $18.51 | $0.00 |
DisclosureSEC source: 0000899243-22-004669 · doc4.xml · derivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option vests in equal monthly installments through February 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
| January 18, 2021 Filed Jan 22, 2021 00:33 UTC | Viridian Therapeutics, Inc.\DE VRDN · Entity 4316 | GrantEmployee Stock Option (right to buy) · Derivative | 356,000 | $0.00 Strike: $23.03 | $0.00 |
DisclosureSEC source: 0000899243-21-002770 · doc4.xml · derivative · entry 1 Katz Barrett · CIK 0001841628 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,000 Underlying: Common Stock · 356,000 shares Expires 2031-01-17 F1 · derivative.exercise_date: The option vests 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.